

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DC-0190
Inventors: Hamilton and Stanton
Serial No.: Not Yet Assigned
Filing Date: Herewith
Examiner: Not Yet Assigned
Group Art Unit: Not Yet Assigned
Title: Compositions and Methods for Modulating
ATP-Binding Cassette Transmembrane
Reporter Protein Expression

"Express Mail" Label No. EV108557407US
Date of Deposit March 28, 2002

I hereby certify that this paper is being deposited with the
United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to the U.S. Patent and
Trademark Office, Box 2327, Arlington, VA 22202

By Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three

months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is set forth below; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: March 28, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. DC-0190	Serial No. Not Yet Assigned
		Applicant Hamilton et al.	
		Filing Date Herewith	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Akabas M., "Channel-linking residues in the M3 membrane-spanning segment of the cystic fibrosis transmembrane conductance regulator", <i>Biochemistry</i> 1998 37(35)	
	AB	Chen et al., "In situ biochemical demonstration that P-Glycoprotein is a drug efflux pump with broad specificity", <i>J. of Cell Biol.</i> 2000 148(5):863-870	
	AC	Kollen et al., "High-efficiency transfer of cystic fibrosis transmembrane conductance regulator cDNA into cystic fibrosis airway cells in culture using lactosylated polylysine as a vector", <i>Human Gene Therapy</i> 1999 10:615-622	
	AD	Wang et al., "Expression and purification of the first nucleotide-binding domain and linker region of human multidrug resistance gene product: comparison of fusions to glutathione S-transferase, thioredoxin and maltose-binding protein", <i>Biochem J.</i> 1999 338:77-81	
EXAMINER		DATE CONSIDERED	

Sheet 01 of 02

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. DC-0190	Serial No. Not Yet Assigned
	Applicant Hamilton et al.	
	Filing Date Herewith	Group Not Yet Assigned

U. S. PATENT DOCUMENTS

Examiner		Document	Date	Name	Class	Subclass
	AA	5,972,598	10-26-99	Chaudhary		
	AB	6,093,567	7-25-00	Gregory		

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	

EXAMINER	DATE CONSIDERED
----------	-----------------